DaVita (NYSE:DVA) Stock Price Down 3.9% – What’s Next?

DaVita Inc. (NYSE:DVA)’s share price dropped 3.9% during mid-day trading on Tuesday. The company traded as low as $187.91 and last traded at $179.6140. 103,555 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 882,677 shares. The stock had previously closed at $187.00.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DVA. Truist Financial cut their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Barclays raised their price objective on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Oppenheimer set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 9th. Finally, Raymond James Financial set a $220.00 target price on DaVita in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, DaVita presently has an average rating of “Moderate Buy” and a consensus target price of $233.43.

DaVita Trading Down 5.4%

The business has a fifty day moving average of $180.54 and a 200-day moving average of $191.07. The firm has a market cap of $11.28 billion, a PE ratio of 14.59, a PEG ratio of 0.49 and a beta of 0.80.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same quarter in the previous year, the firm earned $2.95 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts forecast that DaVita Inc. will post 14.57 EPS for the current year.

Institutional Trading of DaVita

Hedge funds and other institutional investors have recently bought and sold shares of the company. Value Investment Professionals LLC lifted its stake in DaVita by 2.0% in the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after acquiring an additional 50 shares during the last quarter. Kesler Norman & Wride LLC grew its holdings in DaVita by 0.8% during the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after acquiring an additional 55 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of DaVita by 1.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company’s stock valued at $560,000 after purchasing an additional 60 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of DaVita by 4.1% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock valued at $426,000 after purchasing an additional 76 shares during the last quarter. Finally, CoreCap Advisors LLC raised its holdings in shares of DaVita by 161.7% in the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock valued at $27,000 after purchasing an additional 97 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.